Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron

Regeneron, Bayer offer more promising data for aging eye drug

Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.

Tribune News Service

Top Funds Focus Their Cash On These Three Sectors

The best mutual funds are scooping up medical, financial and energy names. But they have their eyes on these other sectors.

Investors Business Daily

Regeneron Sinks Despite Massive Earnings Beat On A Notable Blockbuster Miss

Regeneron Pharma topped third-quarter expectations Thursday, reporting less of a decline than expected. But REGN stock was down early.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments.

Investors Business Daily

A Colorado teen’s long COVID isn’t just persisting — after 2 years, it’s getting worse

DENVER -- Reminders of life outside Lilly Downs’ Denver hospital room dotted the walls.

The Denver Post

Regeneron's Eylea Win Leaves an Elephant in the Room

Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.

The Street

Regeneron Stock Soars On Pair Of Successful Trials

Studies "support aflibercept 8 mg as a potential new standard-of-care," Regeneron Pharmaceuticals said. Regeneron stock leapt in huge volume.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Benzinga

Regeneron Soars As Eylea Outplays Competition, Both Beating Forecasts And Growing

Regeneron Pharmaceuticals outplayed its competition in eye diseases Wednesday, reporting Eylea sales that beat, leading REGN stock to soar.

Investors Business Daily

How Donald Trump’s fight with Covid unfolded two years before Biden diagnosis

Low blood oxygen levels and lung issues led officials to believe Trump might have to be put on ventilator in 2020

The Independent UK

Could The Next CRISPR From Verve, Beam Signal The End To High Cholesterol?

Verve Therapeutics said Tuesday it edited the genes of someone with high cholesterol. The first-ever move could push VERV stock higher.

Investors Business Daily

Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?

The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.

Investors Business Daily

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Benzinga

U.S. FDA Accepts Regeneron's Diabetic Retinopathy Candidate Submission For Review

The U.S. Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ (NASDAQ: REGN) supplemental Biologics License Application (sBLA) of EYLEA (aflibercept) Injection for review in patients with diabetic retinopathy (DR).

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children

The U.S.

Investors Business Daily

Stock Market Near Session Lows; These Health Care Leaders Tumble

The stock market gave back most of its early gains and traded near session lows in afternoon trading. Amazon.com rose in the first day of its stock split.

Investors Business Daily

Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer

Regeneron stock tumbled Thursday after the company announced a deal to acquire the international rights to Sanofi-partnered cancer drug Libtayo.

Investors Business Daily

Oil Stocks Lead Charge Of Breakouts And Buy Zones In New Uptrend

With a new uptrend underway, oil stocks like TotalEnergies and tech stocks like Synopsys set the stage for new breakouts.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease

The U.S.

Benzinga

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

Investors Business Daily

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now

AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

Benzinga

Regeneron Posts Drop In Q1 Profit As COVID Antibody Sales Hit, Shares Fall

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $11.49 per share for Q1 FY22, up 16% Y/Y, beating the $10.04 estimate. Sales increased 17% to $2.96 billion, surpassing the analysts' consensus of $2.73 billion, fueled by sales of COVID-19 treatment, REGEN-COV. The company reported a net income of $974 million, down 13%, as its COVID-19…

Investors Business Daily

Why The First Quarter Could Be A 'High-Water Mark' For Regeneron

The first quarter could represent a "high-water mark" for Regeneron Pharmaceuticals, an analyst said Wednesday.

Benzinga

Here's Why This Analyst Cut Price Target On Regeneron

RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc's price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating. Checks suggest that Dupixent (dupilumab) growth/durability should remain strong in new and existing indications, maintaining positive sentiment. The analysts also believe that the concerns about near-term Eylea competition may be overblown. However, high-dose…

Benzinga

The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu

Here's a roundup of top developments in the biotech space over the last 24 hours.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.